CNS biotech Myrobalan Therapeutics raises $24M Series A to enter the clinic
Myrobalan Therapeutics has raised $24 million to enter the clinic with one of its four CNS therapeutic candidates, with the goal of either repairing or restoring functions in patients with neurodegenerative conditions.
Medford, MA-based Myrobalan was formed in mid-2021 and is based on findings out of Harvard researcher Zhigang He, and has staff in China as well as the US. It’s a reunion of sorts for CEO Jing Wang, an 18-year biotech veteran who did her PhD in He’s lab in the early 2000s. The biotech’s other co-founder is MIT professor Guoping Feng.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.